PT  - JOURNAL ARTICLE
AU  - Koenn, Mary E
TI  - Fetal Fibronectin
AID  - 10.29074/ascls.15.2.96
DP  - 2002 Apr 01
TA  - American Society for Clinical Laboratory Science
PG  - 96--115
VI  - 15
IP  - 2
4099  - http://hwmaint.clsjournal.ascls.org/content/15/2/96.short
4100  - http://hwmaint.clsjournal.ascls.org/content/15/2/96.full
SO  - Clin Lab Sci2002 Apr 01; 15
AB  - OBJECTIVES: The objectives of this review paper are to: describe the fetal fibronectin assay, its purpose, and clinical significance; evaluate the sensitivity and specificity of the fetal fibronectin test; describe the specimen collection and measurement of the fetal fibronectin test; and present the advantages and disadvantages of incorporating fetal fibronectin testing in routine prenatal care.DATA SOURCES: Current literature.DATA SYNTHESIS: Fibronectin proteins function in plasma and extracellular matrix in cell adhesion and migration. Recently, a fibronectin protein has been evaluated and proposed as a predictor of preterm delivery. A simple, qualitative assay detects this protein, fetal fibronectin, in cervicovaginal secretions of women who are at risk for or have symptoms of preterm delivery. The test is positive when there has been a rupture in the membranes attaching the fetus to the uterus, thus indicating pending preterm delivery. Sensitivity and specificity studies have been performed to evaluate its reliable prediction of preterm delivery.CONCLUSION: Evaluation of sensitivity and specificity studies document that the fetal fibronectin test predicts preterm delivery. For symptomatic women, a sensitivity of 89% and specificity of 86% was found.ABBREVIATIONS: fFN = fetal fibronectin; PTD = preterm delivery.